中草药

肠道菌群-肠道屏障互作在溃疡性结肠炎中的作用及中医药干预研究进展

PDF下载

张欣然 ¹,,² , 王艺璇 ¹, , 陈嘉屿 ¹,

中草药 | 综述 2026,57(16): 6632-6646

收起

中草药 |综述 2026 , 57 (16) : 6632 -6646

肠道菌群-肠道屏障互作在溃疡性结肠炎中的作用及中医药干预研究进展

全屏

[Author(id=1319981921036251679, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=张欣然, orcid=null, stid=null, country=null, authorPic=null, dead=null, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=2, ext={CN=AuthorExt(id=1319981921417933346, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, authorId=1319981921036251679, language=CN, stringName=张欣然, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹,,², address=³,^2.甘肃中医药大学中西医结合学院, 甘肃兰州 730000中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050, bio=张欣然: 张欣然,硕士研究生,研究方向为中西医结合防治消化系统疾病研究。E-mail:zzxzxr2026@163.com, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319981920621015581, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, xref=3^*, ext=[AuthorCompanyExt(id=1319981920646181406, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, companyId=1319981920621015581, language=CN, country=null, province=null, city=null, postcode=null, companyName=中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050, departmentName=null, remark=^3.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050)]), AuthorCompany(id=1319981920201585179, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, xref=2, ext=[AuthorCompanyExt(id=1319981920209973788, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, companyId=1319981920201585179, language=CN, country=null, province=null, city=null, postcode=null, companyName=甘肃中医药大学中西医结合学院, 甘肃兰州 730000, departmentName=null, remark=^2.甘肃中医药大学中西医结合学院, 甘肃兰州 730000)])]), Author(id=1319981923133403683, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=王艺璇, orcid=null, stid=null, country=null, authorPic=null, dead=null, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=2, ext={CN=AuthorExt(id=1319981923557028389, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, authorId=1319981923133403683, language=CN, stringName=王艺璇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹,, address=³中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319981920621015581, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, xref=3^*, ext=[AuthorCompanyExt(id=1319981920646181406, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, companyId=1319981920621015581, language=CN, country=null, province=null, city=null, postcode=null, companyName=中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050, departmentName=null, remark=^3.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050)])]), Author(id=1319981924026790438, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=陈嘉屿, orcid=null, stid=null, country=null, authorPic=null, dead=null, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=2, ext={CN=AuthorExt(id=1319981924345557544, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, authorId=1319981924026790438, language=CN, stringName=陈嘉屿, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹,, address=³中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319981920621015581, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, xref=3^*, ext=[AuthorCompanyExt(id=1319981920646181406, tenantId=1146029695717560320, journalId=1302319053441957962, articleId=1319981916057612821, companyId=1319981920621015581, language=CN, country=null, province=null, city=null, postcode=null, companyName=中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050, departmentName=null, remark=^3.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050)])])]

张欣然¹,,², 王艺璇¹,, 陈嘉屿¹,

作者信息

^1.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050

^2.甘肃中医药大学中西医结合学院, 甘肃兰州 730000

^3.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050

通讯作者:

王艺璇

作者简介:

张欣然: 张欣然,硕士研究生,研究方向为中西医结合防治消化系统疾病研究。E-mail:zzxzxr2026@163.com

Research progress on role of gut microbiota-intestinal barrier interaction in ulcerative colitis and intervention with traditional Chinese medicine

Affiliations

出版时间: 2026-08-28 doi: 10.7501/j.issn.0253-2670.2026.16.033

文章导航

摘要

收起

溃疡性结肠炎（ulcerative colitis，UC）是一种慢性非特异性肠道炎症性疾病，肠道菌群紊乱与肠道屏障功能障碍形成的恶性循环是其迁延难愈的核心病理机制之一，菌群多样性降低、有益菌减少、致病菌增多，导致短链脂肪酸、色氨酸等代谢紊乱，进而破坏黏液层、紧密连接蛋白及免疫屏障功能，加重炎症。中医药基于“浊毒理论”等核心病机，通过重塑菌群结构，促进有益代谢产物生成，上调紧密连接蛋白表达等途径发挥治疗作用，有效阻断恶性循环。系统综述了UC中肠道菌群与肠道屏障的相互作用，以及中医药的干预理论与现代生物学机制，为UC的中医药治疗提供理论参考，凸显其临床应用潜力。

关键词

溃疡性结肠炎 / 肠道菌群 / 肠道屏障 / 中医药 / 肠道菌群紊乱

Abstract

收起

Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease. A vicious cycle driven by gut microbiota dysbiosis and disruption of the intestinal barrier is considered a key mechanism underlying its recurrent and refractory nature. Reduced microbial diversity, decreased beneficial bacteria, and increased pathogenic taxa lead to disturbances in metabolites such as short-chain fatty acids and tryptophan, which subsequently impair the mucus layer, tight junction proteins, and immune barrier function, further aggravating mucosal inflammation. According to traditional Chinese medicine (TCM), core pathogenic factors such as “turbidity‑toxin theory” play central roles in UC. Guided by these principles, TCM therapies intervene through multiple approaches, including reshaping gut microbial composition, enhancing the production of beneficial metabolites, and upregulating tight junction proteins. These actions contribute to breaking the aforementioned vicious cycle. This review systematically summarizes the interactions between gut microbiota and the intestinal barrier in UC, as well as the theoretical basis and modern biological mechanisms by which TCM exerts therapeutic effects. The findings provide a theoretical reference for the application of TCM in UC management and highlight its potential clinical value.

Key words

ulcerative colitis / gut microbiota / intestinal barrier / traditional Chinese medicine / gut microbiota imbalance

引用本文

张欣然, 王艺璇, 陈嘉屿. 肠道菌群-肠道屏障互作在溃疡性结肠炎中的作用及中医药干预研究进展. 中草药, 2026 , 57 (16) : 6632 -6646 . DOI: 10.7501/j.issn.0253-2670.2026.16.033

ZHANG Xinran, WANG Yixuan, CHEN Jiayu. Research progress on role of gut microbiota-intestinal barrier interaction in ulcerative colitis and intervention with traditional Chinese medicine[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (16) : 6632 -6646 . DOI: 10.7501/j.issn.0253-2670.2026.16.033

基金

收起

国家自然科学基金青年基金项目
兰州市科技计划项目

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Gong M, Zhang F R, Miao Y L, et al. Advances of heat shock family in ulcerative colitis [J]. Front Pharmacol, 2022, 13: 869930.

唐立, 陆岩, 欧阳满照. 细胞焦亡与溃疡性结肠炎研究的最新进展[J]. 广东医学, 2021, 42(11): 1393-1399.

中国溃疡性结肠炎诊治指南(2023年·西安) [J]. 胃肠病学, 2024, 29(3): 145-173.

Olén O, Erichsen R, Sachs M C, et al. Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study [J]. Lancet, 2020, 395(10218): 123-131.

Ungaro R, Mehandru S, Allen P B, et al. Ulcerative colitis [J]. Lancet, 2017, 389(10080): 1756-1770.

Kaplan G G. The global burden of IBD: From 2015 to 2025[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12): 720-727.

Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: Clinical biomarkers, therapeutic targets, and emerging treatments [J]. Trends Pharmacol Sci, 2024, 45(10): 892-903.

Li D F, Chang X, Zhao J L, et al. Colonic epithelial PHLPP2 deficiency promotes colonic epithelial pyroptosis by activating the NF-κB signaling pathway [J]. Oxid Med Cell Longev, 2021, 2021: 5570731.

Zhou Y C, Zhang D D, Cheng H, et al. Repairing gut barrier by traditional Chinese medicine: Roles of gut microbiota [J]. Front Cell Infect Microbiol, 2024, 14: 1389925.

Knox N C, Forbes J D, Peterson C L, et al. The gut microbiome in inflammatory bowel disease: Lessons learned from other immune-mediated inflammatory diseases [J]. Am J Gastroenterol, 2019, 114(7): 1051-1070.

Li M X, Li M Y, Lei J X, et al. Huangqin Decoction ameliorates DSS-induced ulcerative colitis: Role of gut microbiota and amino acid metabolism, mTOR pathway and intestinal epithelial barrier [J]. Phytomedicine, 2022, 100: 154052.

Tie Y Z, Huang Y L, Chen R R, et al. Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: Pathophysiology and therapeutic targets [J]. Gut Microbes, 2023, 15(2): 2265028.

de Vos W M, Tilg H, Van Hul M, et al. Gut microbiome and health: Mechanistic insights [J]. Gut, 2022, 71(5):1020-1032.

Chandrasekaran P, Weiskirchen S, Weiskirchen R.Effects of probiotics on gut microbiota: An overview [J]. Int J Mol Sci, 2024, 25(11): 6022.

Lee Y, Kamada N, Moon J J. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome [J]. Adv Drug Deliv Rev, 2021, 179: 114021.

Ma J Y, Piao X S, Mahfuz S, et al. The interaction among gut microbes, the intestinal barrier and short chain fatty acids [J]. Anim Nutr, 2022, 9: 159-174.

赵鲁卿, 丁宁, 师浩然, 等. 《中医药治疗溃疡性结肠炎国际临床实践指南(2023)》解读[J]. 世界中医药, 2025, 20(3): 368-375.

郑智礼, 李洪峥, 王少丽, 等. 从“脾虚湿盛”到“瘀毒蚀络”：溃疡性结肠炎全程治疗策略的动态管理路径[J/OL]. 中国实验方剂学杂志, (2025-11-24) [2026-05-28]. https://doi.org/10.13422/j.cnki.syfjx.20260592.

董笑一, 赵丹阳, 霍永利, 等. 国医大师李佃贵教授基于“中虚-浊阻-毒生” 论治溃疡性结肠炎经验探析[J]. 天津中医药, 2025, 42(6): 686-689.

沈洪, 胡静怡, 朱磊, 等. 中医药治疗溃疡性结肠炎的研究现状、挑战与策略[J]. 南京中医药大学学报, 2025, 41(10):1267-1273.

郭美薇, 刘凡铭, 邹伟. 16SrRNA测序技术在肠道菌群检测中的研究进展[J]. 实验室科学, 2019, 22(2): 1-4.

Iliev I D, Ananthakrishnan A N, Guo C J. Microbiota in inflammatory bowel disease: Mechanisms of disease and therapeutic opportunities [J]. Nat Rev Microbiol, 2025, 23(8): 509-524.

Michail S, Durbin M, Turner D, et al. Alterations in the gut microbiome of children with severe ulcerative colitis [J]. Inflamm Bowel Dis, 2012, 18(10): 1799-1808.

Bu F, Chen K Y, Chen S C, et al. Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment [J]. Front Cell Infect Microbiol, 2025, 15:1565082.

罗玉婷. 基于“肠道菌群: 代谢: 炎症”探索半夏泻心汤治疗溃疡性结肠炎的作用机制[D]. 北京: 中国中医科学院, 2024.

Vich Vila A, Imhann F, Collij V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome [J]. Science Translational Medicine, 2018, 10(472): eaap8914.

Xu N, Xiao X P, Ma Y, et al. Advancements in understanding the relationship between Akkermansia muciniphila and the development of ulcerative colitis [J]. Front Pediatr, 2025, 13:1673156.

Bajaj A, Markandey M, Kedia S, et al. Gut bacteriome in inflammatory bowel disease: An update on recent advances [J]. Indian J Gastroenterol, 2024, 43(1): 103-111.

Guo X Y, Liu X J, Hao J Y. Gut microbiota in ulcerative colitis: Insights on pathogenesis and treatment [J]. J Dig Dis, 2020, 21(3): 147-159.

Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD [J]. Gut, 2017, 66(6): 1039-1048.

Norman J M, Handley S A, Baldridge M T, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease [J]. Cell, 2015, 160(3): 447-460.

Wu J Y, Wang K, Wang X M, et al. The role of the gut microbiome and its metabolites in metabolic diseases [J]. Protein Cell, 2021, 12(5): 360-373.

Ikeda T, Nishida A, Yamano M, et al. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases [J]. Pharmacol Ther, 2022, 239: 108273.

Zhang D, Jian Y P, Zhang Y N, et al. Short-chain fatty acids in diseases [J]. Cell Commun Signal, 2023, 21(1): 212.

Parada Venegas D, De la Fuente M K, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases [J]. Frontiers Immunol, 2019, 10: 277.

Recharla N, Geesala R, Shi X Z. Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: A literature review [J]. Nutrients, 2023, 15(10): 2275.

Peng K X, et al. Butyrate inhibits the HDAC8/NF-κB pathway to enhance Slc26a3 expression and improve the intestinal epithelial barrier to relieve colitis [J]. J Agric Food Chem, 2024, 72(44): 24400-24416.

Scott S A, Fu J J, Chang P V. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor [J]. Proc Natl Acad Sci USA, 2020, 117(32): 19376-19387.

Zheng M Q, Zhai Y J, Yu Y B, et al. TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response [J]. Cell Metab, 2024, 36(9): 2086-2103.

Sinha S R, Haileselassie Y, Nguyen L P, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation [J]. Cell Host Microbe, 2020, 27(4): 659-670.e5.

Aburto M R, Cryan J F. Gastrointestinal and brain barriers: Unlocking gates of communication across the microbiota-gut-brain axis [J]. Nat Rev Gastroenterol Hepatol, 2024, 21(4): 222-247.

覃晓日, 邝继孙, 毛苇, 等. 黏蛋白2介导TLR4/ MyD88/NF-κB通路缓解小鼠溃疡性结肠炎[J]. 海南医学, 2025, 36(18): 2592-2603.

宁可. 马齿苋对DSS诱导的溃疡性结肠炎的缓解作用及其机制研究[D]. 长春: 吉林大学, 2024.

Alam A, Neish A. Role of gut microbiota in intestinal wound healing and barrier function [J]. Tissue Barriers, 2018, 6(3): 1539595.

Landy J, Ronde E, English N, et al. Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer [J]. World J Gastroenterol, 2016, 22(11):3117.

Neurath M F. Targeting immune cell circuits and trafficking in inflammatory bowel disease [J]. Nat Immunol, 2019, 20(8):970-979.

Hou Q H, Huang J X, Ayansola H, et al. Intestinal stem cells and immune cell relationships: Potential therapeutic targets for inflammatory bowel diseases [J]. Front Immunol, 2021, 11:623691.

Liang J, Dai W G, Liu C H, et al. Gingerenone a attenuates ulcerative colitis via targeting IL-17RA to inhibit inflammation and restore intestinal barrier function [J]. Adv Sci, 2024, 11(28): 2400206.

Badr-el-Din S, Trejdosiewicz L K, Heatley R V, et al. Local immunity in ulcerative colitis: Evidence for defective secretory IgA production [J]. Gut, 1988, 29(8): 1070-1075.

Zhang Y, Zhou Z H, Zhang Z M, et al. Lentinan mitigates ulcerative colitis via the IL-22 pathway to repair the compromised mucosal barrier and enhance antimicrobial defense [J]. Int J Biol Macromol, 2025, 307: 141784.

Menta P L R, Andrade M E R, Leocádio P C L, et al. Wheat gluten intake increases the severity of experimental colitis and bacterial translocation by weakening of the proteins of the junctional complex [J]. Br J Nutr, 2019, 121(4): 361-373.

Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon [J]. Gut, 2007, 56(3): 343-350.

Zhou C, Peng B, Zhang M X, et al. Ganjiang Huangqin Huanglian Renshen Decoction protects against ulcerative colitis by modulating inflammation, oxidative stress, and gut microbiota [J]. Phytomedicine, 2024, 135: 156172.

李军祥, 唐旭东, 王化虹, 等. 溃疡性结肠炎中医诊疗指南（2023）附视频[J]. 中医杂志, 2024, 65(7): 763-768.

高金栋, 周天羽, 张玮琦, 等. 基于“浊毒”理论探究中性粒细胞胞外诱捕网与溃疡性结肠炎的关系[J]. 中医药信息, 2025, 42(11):62-68.

王建成, 齐洪军, 郭洁洁. 溃疡性结肠炎的中医药治疗研究进展[J]. 实用中医内科杂志, 2024, 38(2): 106-109.

甄建华, 黄光瑞. 溃疡性结肠炎中医病名、病因、病机的古今比较和回顾[J]. 环球中医药, 2019, 12(8): 1286-1289.

张丽娟. 溃疡性结肠炎内镜下表现与中医证型的相关性研究[D]. 济南: 山东中医药大学, 2016.

马文源, 刘坤静, 王春雨, 等. 溃疡性结肠炎中医病机述要[J]. 中国中西医结合消化杂志, 2025(9): 855-859.

张伟, 邹孟龙, 周耀, 等. 从“虚、毒、瘀” 理论与中性粒细胞胞外诱捕网辨治溃疡性结肠炎[J]. 中药药理与临床, 2025, 41(12): 99-105.

刘朝霞, 张雪艳, 宋蕾. 谢晶日教授治疗缓解期溃疡性结肠炎(脾肾阳虚证)经验举隅[J]. 中国中医急症, 2019, 28(1): 136-137.

中国中西医结合学会. 溃疡性结肠炎中西医结合诊疗专家共识附视频[J]. 中国中西医结合杂志, 2023, 43(1): 5-11.

李佃贵. 从浊毒理论的建立与应用谈中医学创新与发展[J]. 中医杂志, 2020, 61(22): 1938-1940.

和柳婷, 赵静, 白海燕, 等. 基于浊毒理论辨治溃疡性结肠炎的诊治研究进展[J]. 临床误诊误治, 2026, 39(4): 101-105.

娄莹莹, 李佃贵, 霍永利, 等. 溃疡性结肠炎特色病机“浊毒损膜伤络” 及其意义[J]. 中国中西医结合杂志, 2022, 42(6): 749-753.

贾雪梅, 郭榆西, 王杰, 等. “肠道菌群-细胞焦亡”与溃疡性结肠炎“浊毒内蕴”病因病机[J]. 中国中西医结合杂志, 2024, 44(4): 475-480.

张亮, 王莹, 路童, 等. 基于“脾主为卫”理论解析肠黏膜多维屏障稳态失衡介导衰老的肠-免疫轴机制[J]. 世界科学技术-中医药现代化, 2026, 28(2): 364-373.

孙春全, 谢雁鸣, 刘龙涛. 基于“肠道菌群-脏腑-浊毒”的高血压病理论探究[J]. 中华中医药杂志, 2021, 36(10):5981-5983.

文娜, 黄超群, 胡运莲. 基于中医病性探讨溃疡性结肠炎与肠道菌群关系以及粪菌寒热属性[J]. 中医药导报, 2025, 31(1): 153-157.

张涛, 于永铎. 基于肠道菌群从脾为之卫治疗溃疡性结肠炎[J]. 实用中医内科杂志, 2025, 39(8): 126-129.

钟迪雅, 于永铎. 基于肠道菌群探讨从脾论治溃疡性结肠炎[J]. 现代中西医结合杂志, 2025, 34(22): 3168-3174.

王晓羽, 侯佳佳, 李海龙, 等. 基于肠道菌群探讨中医内生湿邪的物质基础[J]. 现代中医药, 2025, 45(4): 64-68.

赵志敏. 溃疡性结肠炎常见中医证型调查及其与肠道菌群的相关性研究[J]. 四川中医, 2021, 39(8):52-55.

杨振寰. 两种中医证型uc患者炎症反应与肠道菌群和胆汁酸代谢的相关性研究[D]. 北京: 北京中医药大学, 2021.

佘美龄, 戴心怡, 陈婷, 等. 溃疡性结肠炎湿热病机与湿热伏邪理论的现代研究[J]. 中国中西医结合杂志, 2026, 46(5): 600-604.

李歌, 席作武, 曹琳果, 等. 肠道菌群与化浊解毒理论视角下溃疡性结肠炎发病机制及疗效研究[J]. 辽宁中医药大学学报, 2026, 28(5): 124-130.

贾雪梅. 基于肠道菌群与细胞焦亡调控代谢物探讨化浊解毒方治疗溃疡性结肠炎的作用机制[D]. 石家庄: 河北中医药大学, 2023.

Hu J Y, Chen H X, Zhu L, et al. Baitouweng Decoction modulates gut microbial production of indole-3-propionic acid and epithelial necroptosis to alleviate DSS-induced colitis in mice [J]. Chin Med, 2025, 20(1): 119.

郑敏, 赵琰, 李彤, 等. 葛根红藤解毒汤对浊毒内蕴型溃疡性结肠炎患者血清NLRP3炎症小体、IL-18、IL-1β及对肠道菌群、黏膜屏障的影响[J]. 中国中西医结合消化杂志, 2024, 32(1): 30-34.

尚立宇. 基于TLR4/NF-κB/NLRP3信号通路探讨四神丸改善肠道菌群结构防治脾肾阳虚型UC小鼠的机制研究[D]. 兰州: 甘肃中医药大学, 2025.

Huang H J, Yang C Y, Li S L, et al. Lizhong Decoction alleviates experimental ulcerative colitis via regulating gut microbiota-SCFAs-Th17/Treg axis [J]. J Ethnopharmacol, 2025, 349:119958.

华明柳, 沈杰, 赵园园. 大黄附子汤合桃花汤加味对溃疡性结肠炎患者肠道菌群及肠屏障功能的影响[J]. 中医药学报, 2023, 51(6): 84-88.

Luo Y T, Fu S, Liu Y L, et al. Banxia Xiexin Decoction modulates gut microbiota and gut microbiota metabolism to alleviate DSS-induced ulcerative colitis [J]. J Ethnopharmacol, 2024, 326: 117990.

Wang X J, Huang S W, Zhang M L, et al. Gegen Qinlian Decoction activates AhR/IL-22 to repair intestinal barrier by modulating gut microbiota-related tryptophan metabolism in ulcerative colitis mice [J]. J Ethnopharmacol, 2023, 302: 115919.

Chen W, Xu L, Wang L, et al. Qing-Re-Hua-Shi Decoction ameliorates DSS-induced colitis by modulating multiple signaling pathways and remodeling the gut microbiota and metabolite profile [J]. Front Cell Infect Microbiol, 2025, 15: 1541289.

Jiao C H, Zhang Q W, Yang M J, et al. Shenling Baizhu San ameliorates ulcerative colitis by regulating the gut microbiota and its tryptophan metabolites: A complementary medicine to mesalamine [J]. J Ethnopharmacol, 2022, 291: 115145.

Cui L, Guan X N, Ding W B, et al. Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota [J]. Int J Biol Macromol, 2021, 166: 1035-1045.

Li Z Y, Lin L H, Liang H J, et al. Lycium barbarum polysaccharide alleviates DSS-induced chronic ulcerative colitis by restoring intestinal barrier function and modulating gut microbiota [J]. Ann Med, 2023, 55(2): 2290213.

Zhang Q W, Yang M J, Liao C Y, et al. Atractylodes macrocephala Koidz polysaccharide ameliorates DSS-induced colitis in mice by regulating the gut microbiota and tryptophan metabolism [J]. British J Pharmacology, 2025, 182(7): 1508-1527.

Wu H, Li Y L, Wang Y, et al. Anemoside B4 alleviates ulcerative colitis by attenuating intestinal oxidative stress and NLRP3 inflammasome via activating aryl hydrocarbon receptor through remodeling the gut microbiome and metabolites [J]. Redox Biol, 2025, 85: 103746.

Cheng H, Liu J, Zhang D D, et al. Ginsenoside Rg₁ alleviates acute ulcerative colitis by modulating gut microbiota and microbial tryptophan metabolism [J]. Front Immunol, 2022, 13: 817600.

Wang C X, Liu H L, Li Z Q, et al. Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation [J]. Biomed Pharmacother, 2024, 180: 117534.

Dong Y L, Fan H, Zhang Z, et al. Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway [J]. Int J Biol Sci, 2022, 18(4): 1381-1397.

Li C L, Deng L, Pu M, et al. Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome [J]. J Ethnopharmacol, 2024, 335: 118680.

Mao N, Yu Y, He J, et al. Matrine ameliorates DSS-induced colitis by suppressing inflammation, modulating oxidative stress and remodeling the gut microbiota [J]. Inter J Mol Sci, 2024, 25(12): 6613.

Wu Z H, Huang S M, Li T T, et al. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis [J]. Microbiome, 2021, 9(1): 184.

Qu Y F, Li X Y, Xu F Y, et al. Kaempferol alleviates murine experimental colitis by restoring gut microbiota and inhibiting the LPS-TLR4-NF-κB axis [J]. Front Immunol, 2021, 12: 679897.

He X D, Li M, Zuo X D, et al. Kushenol I combats ulcerative colitis via intestinal barrier preservation and gut microbiota optimization [J]. World J Gastroenterol, 2025, 31(26): 105656.

Su Y L, Liang J J, Zhang M L, et al. Wogonin regulates colonocyte metabolism via PPARγ to inhibit Enterobacteriaceae against dextran sulfate sodium-induced colitis in mice [J]. Phytother Res, 2023, 37(3): 872-884.

100

Wang W P, Xia T S, Yu X P. Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-κB pathway in vitro [J]. Inflamm Res, 2015, 64(6): 423-431.

101

Jia Y H, Liu X J, Gao X Y, et al. Plantamajoside alleviates DSS-induced ulcerative colitis by modulating gut microbiota, upregulating CBS, and inhibiting NF-κB [J]. Phytomedicine, 2025, 143: 156827.

102

姜佳恩. 基于PI3K/AKT、TRL4/NF-κB通路黄芪-青黛内外联合治疗溃疡性结肠炎的作用机制[D]. 南昌: 江西中医药大学, 2024.

103

李红燕. 黄连配伍厚朴调控溃疡性结肠炎肠道菌群的作用机制研究[D]. 成都: 成都中医药大学, 2021.

104

魏海梁, 李京涛, 陈志国, 等. 小檗碱与6-姜烯酚配伍对溃疡性结肠炎小鼠肠道炎症和菌群影响的实验研究[J]. 中国中药杂志, 2022, 47(16):4418-4427.

105

Jiang Y W, Xu H C, Wu J L, et al. A hierarchically assembled oral formulation with drug-convertible carriers for targeted ulcerative colitis therapy through a three-pronged strategy [J]. Adv Compos Hybrid Mater, 2025, 8(4): 280.

Gong M, Zhang F R, Miao Y L, et al. Advances of heat shock family in ulcerative colitis [J]. Front Pharmacol, 2022, 13: 869930.
唐立, 陆岩, 欧阳满照. 细胞焦亡与溃疡性结肠炎研究的最新进展[J]. 广东医学, 2021, 42(11): 1393-1399.
中国溃疡性结肠炎诊治指南(2023年·西安) [J]. 胃肠病学, 2024, 29(3): 145-173.
Olén O, Erichsen R, Sachs M C, et al. Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study [J]. Lancet, 2020, 395(10218): 123-131.
Ungaro R, Mehandru S, Allen P B, et al. Ulcerative colitis [J]. Lancet, 2017, 389(10080): 1756-1770.
Kaplan G G. The global burden of IBD: From 2015 to 2025[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12): 720-727.
Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: Clinical biomarkers, therapeutic targets, and emerging treatments [J]. Trends Pharmacol Sci, 2024, 45(10): 892-903.
Li D F, Chang X, Zhao J L, et al. Colonic epithelial PHLPP2 deficiency promotes colonic epithelial pyroptosis by activating the NF-κB signaling pathway [J]. Oxid Med Cell Longev, 2021, 2021: 5570731.
Zhou Y C, Zhang D D, Cheng H, et al. Repairing gut barrier by traditional Chinese medicine: Roles of gut microbiota [J]. Front Cell Infect Microbiol, 2024, 14: 1389925.
Knox N C, Forbes J D, Peterson C L, et al. The gut microbiome in inflammatory bowel disease: Lessons learned from other immune-mediated inflammatory diseases [J]. Am J Gastroenterol, 2019, 114(7): 1051-1070.
Li M X, Li M Y, Lei J X, et al. Huangqin Decoction ameliorates DSS-induced ulcerative colitis: Role of gut microbiota and amino acid metabolism, mTOR pathway and intestinal epithelial barrier [J]. Phytomedicine, 2022, 100: 154052.
Tie Y Z, Huang Y L, Chen R R, et al. Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: Pathophysiology and therapeutic targets [J]. Gut Microbes, 2023, 15(2): 2265028.
de Vos W M, Tilg H, Van Hul M, et al. Gut microbiome and health: Mechanistic insights [J]. Gut, 2022, 71(5):1020-1032.
Chandrasekaran P, Weiskirchen S, Weiskirchen R.Effects of probiotics on gut microbiota: An overview [J]. Int J Mol Sci, 2024, 25(11): 6022.
Lee Y, Kamada N, Moon J J. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome [J]. Adv Drug Deliv Rev, 2021, 179: 114021.
Ma J Y, Piao X S, Mahfuz S, et al. The interaction among gut microbes, the intestinal barrier and short chain fatty acids [J]. Anim Nutr, 2022, 9: 159-174.
赵鲁卿, 丁宁, 师浩然, 等. 《中医药治疗溃疡性结肠炎国际临床实践指南(2023)》解读[J]. 世界中医药, 2025, 20(3): 368-375.
郑智礼, 李洪峥, 王少丽, 等. 从“脾虚湿盛”到“瘀毒蚀络”：溃疡性结肠炎全程治疗策略的动态管理路径[J/OL]. 中国实验方剂学杂志, (2025-11-24) [2026-05-28]. https://doi.org/10.13422/j.cnki.syfjx.20260592.
董笑一, 赵丹阳, 霍永利, 等. 国医大师李佃贵教授基于“中虚-浊阻-毒生” 论治溃疡性结肠炎经验探析[J]. 天津中医药, 2025, 42(6): 686-689.
沈洪, 胡静怡, 朱磊, 等. 中医药治疗溃疡性结肠炎的研究现状、挑战与策略[J]. 南京中医药大学学报, 2025, 41(10):1267-1273.
郭美薇, 刘凡铭, 邹伟. 16SrRNA测序技术在肠道菌群检测中的研究进展[J]. 实验室科学, 2019, 22(2): 1-4.
Iliev I D, Ananthakrishnan A N, Guo C J. Microbiota in inflammatory bowel disease: Mechanisms of disease and therapeutic opportunities [J]. Nat Rev Microbiol, 2025, 23(8): 509-524.
Michail S, Durbin M, Turner D, et al. Alterations in the gut microbiome of children with severe ulcerative colitis [J]. Inflamm Bowel Dis, 2012, 18(10): 1799-1808.
Bu F, Chen K Y, Chen S C, et al. Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment [J]. Front Cell Infect Microbiol, 2025, 15:1565082.
罗玉婷. 基于“肠道菌群: 代谢: 炎症”探索半夏泻心汤治疗溃疡性结肠炎的作用机制[D]. 北京: 中国中医科学院, 2024.
Vich Vila A, Imhann F, Collij V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome [J]. Science Translational Medicine, 2018, 10(472): eaap8914.
Xu N, Xiao X P, Ma Y, et al. Advancements in understanding the relationship between Akkermansia muciniphila and the development of ulcerative colitis [J]. Front Pediatr, 2025, 13:1673156.
Bajaj A, Markandey M, Kedia S, et al. Gut bacteriome in inflammatory bowel disease: An update on recent advances [J]. Indian J Gastroenterol, 2024, 43(1): 103-111.
Guo X Y, Liu X J, Hao J Y. Gut microbiota in ulcerative colitis: Insights on pathogenesis and treatment [J]. J Dig Dis, 2020, 21(3): 147-159.
Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD [J]. Gut, 2017, 66(6): 1039-1048.
Norman J M, Handley S A, Baldridge M T, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease [J]. Cell, 2015, 160(3): 447-460.
Wu J Y, Wang K, Wang X M, et al. The role of the gut microbiome and its metabolites in metabolic diseases [J]. Protein Cell, 2021, 12(5): 360-373.
Ikeda T, Nishida A, Yamano M, et al. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases [J]. Pharmacol Ther, 2022, 239: 108273.
Zhang D, Jian Y P, Zhang Y N, et al. Short-chain fatty acids in diseases [J]. Cell Commun Signal, 2023, 21(1): 212.
Parada Venegas D, De la Fuente M K, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases [J]. Frontiers Immunol, 2019, 10: 277.
Recharla N, Geesala R, Shi X Z. Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: A literature review [J]. Nutrients, 2023, 15(10): 2275.
Peng K X, et al. Butyrate inhibits the HDAC8/NF-κB pathway to enhance Slc26a3 expression and improve the intestinal epithelial barrier to relieve colitis [J]. J Agric Food Chem, 2024, 72(44): 24400-24416.
Scott S A, Fu J J, Chang P V. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor [J]. Proc Natl Acad Sci USA, 2020, 117(32): 19376-19387.
Zheng M Q, Zhai Y J, Yu Y B, et al. TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response [J]. Cell Metab, 2024, 36(9): 2086-2103.
Sinha S R, Haileselassie Y, Nguyen L P, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation [J]. Cell Host Microbe, 2020, 27(4): 659-670.e5.
Aburto M R, Cryan J F. Gastrointestinal and brain barriers: Unlocking gates of communication across the microbiota-gut-brain axis [J]. Nat Rev Gastroenterol Hepatol, 2024, 21(4): 222-247.
覃晓日, 邝继孙, 毛苇, 等. 黏蛋白2介导TLR4/ MyD88/NF-κB通路缓解小鼠溃疡性结肠炎[J]. 海南医学, 2025, 36(18): 2592-2603.
宁可. 马齿苋对DSS诱导的溃疡性结肠炎的缓解作用及其机制研究[D]. 长春: 吉林大学, 2024.
Alam A, Neish A. Role of gut microbiota in intestinal wound healing and barrier function [J]. Tissue Barriers, 2018, 6(3): 1539595.
Landy J, Ronde E, English N, et al. Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer [J]. World J Gastroenterol, 2016, 22(11):3117.
Neurath M F. Targeting immune cell circuits and trafficking in inflammatory bowel disease [J]. Nat Immunol, 2019, 20(8):970-979.
Hou Q H, Huang J X, Ayansola H, et al. Intestinal stem cells and immune cell relationships: Potential therapeutic targets for inflammatory bowel diseases [J]. Front Immunol, 2021, 11:623691.
Liang J, Dai W G, Liu C H, et al. Gingerenone a attenuates ulcerative colitis via targeting IL-17RA to inhibit inflammation and restore intestinal barrier function [J]. Adv Sci, 2024, 11(28): 2400206.
Badr-el-Din S, Trejdosiewicz L K, Heatley R V, et al. Local immunity in ulcerative colitis: Evidence for defective secretory IgA production [J]. Gut, 1988, 29(8): 1070-1075.
Zhang Y, Zhou Z H, Zhang Z M, et al. Lentinan mitigates ulcerative colitis via the IL-22 pathway to repair the compromised mucosal barrier and enhance antimicrobial defense [J]. Int J Biol Macromol, 2025, 307: 141784.
Menta P L R, Andrade M E R, Leocádio P C L, et al. Wheat gluten intake increases the severity of experimental colitis and bacterial translocation by weakening of the proteins of the junctional complex [J]. Br J Nutr, 2019, 121(4): 361-373.
Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon [J]. Gut, 2007, 56(3): 343-350.
Zhou C, Peng B, Zhang M X, et al. Ganjiang Huangqin Huanglian Renshen Decoction protects against ulcerative colitis by modulating inflammation, oxidative stress, and gut microbiota [J]. Phytomedicine, 2024, 135: 156172.
李军祥, 唐旭东, 王化虹, 等. 溃疡性结肠炎中医诊疗指南（2023）附视频[J]. 中医杂志, 2024, 65(7): 763-768.
高金栋, 周天羽, 张玮琦, 等. 基于“浊毒”理论探究中性粒细胞胞外诱捕网与溃疡性结肠炎的关系[J]. 中医药信息, 2025, 42(11):62-68.
王建成, 齐洪军, 郭洁洁. 溃疡性结肠炎的中医药治疗研究进展[J]. 实用中医内科杂志, 2024, 38(2): 106-109.
甄建华, 黄光瑞. 溃疡性结肠炎中医病名、病因、病机的古今比较和回顾[J]. 环球中医药, 2019, 12(8): 1286-1289.
张丽娟. 溃疡性结肠炎内镜下表现与中医证型的相关性研究[D]. 济南: 山东中医药大学, 2016.
马文源, 刘坤静, 王春雨, 等. 溃疡性结肠炎中医病机述要[J]. 中国中西医结合消化杂志, 2025(9): 855-859.
张伟, 邹孟龙, 周耀, 等. 从“虚、毒、瘀” 理论与中性粒细胞胞外诱捕网辨治溃疡性结肠炎[J]. 中药药理与临床, 2025, 41(12): 99-105.
刘朝霞, 张雪艳, 宋蕾. 谢晶日教授治疗缓解期溃疡性结肠炎(脾肾阳虚证)经验举隅[J]. 中国中医急症, 2019, 28(1): 136-137.
中国中西医结合学会. 溃疡性结肠炎中西医结合诊疗专家共识附视频[J]. 中国中西医结合杂志, 2023, 43(1): 5-11.
李佃贵. 从浊毒理论的建立与应用谈中医学创新与发展[J]. 中医杂志, 2020, 61(22): 1938-1940.
和柳婷, 赵静, 白海燕, 等. 基于浊毒理论辨治溃疡性结肠炎的诊治研究进展[J]. 临床误诊误治, 2026, 39(4): 101-105.
娄莹莹, 李佃贵, 霍永利, 等. 溃疡性结肠炎特色病机“浊毒损膜伤络” 及其意义[J]. 中国中西医结合杂志, 2022, 42(6): 749-753.
贾雪梅, 郭榆西, 王杰, 等. “肠道菌群-细胞焦亡”与溃疡性结肠炎“浊毒内蕴”病因病机[J]. 中国中西医结合杂志, 2024, 44(4): 475-480.
张亮, 王莹, 路童, 等. 基于“脾主为卫”理论解析肠黏膜多维屏障稳态失衡介导衰老的肠-免疫轴机制[J]. 世界科学技术-中医药现代化, 2026, 28(2): 364-373.
孙春全, 谢雁鸣, 刘龙涛. 基于“肠道菌群-脏腑-浊毒”的高血压病理论探究[J]. 中华中医药杂志, 2021, 36(10):5981-5983.
文娜, 黄超群, 胡运莲. 基于中医病性探讨溃疡性结肠炎与肠道菌群关系以及粪菌寒热属性[J]. 中医药导报, 2025, 31(1): 153-157.
张涛, 于永铎. 基于肠道菌群从脾为之卫治疗溃疡性结肠炎[J]. 实用中医内科杂志, 2025, 39(8): 126-129.
钟迪雅, 于永铎. 基于肠道菌群探讨从脾论治溃疡性结肠炎[J]. 现代中西医结合杂志, 2025, 34(22): 3168-3174.
王晓羽, 侯佳佳, 李海龙, 等. 基于肠道菌群探讨中医内生湿邪的物质基础[J]. 现代中医药, 2025, 45(4): 64-68.
赵志敏. 溃疡性结肠炎常见中医证型调查及其与肠道菌群的相关性研究[J]. 四川中医, 2021, 39(8):52-55.
杨振寰. 两种中医证型uc患者炎症反应与肠道菌群和胆汁酸代谢的相关性研究[D]. 北京: 北京中医药大学, 2021.
佘美龄, 戴心怡, 陈婷, 等. 溃疡性结肠炎湿热病机与湿热伏邪理论的现代研究[J]. 中国中西医结合杂志, 2026, 46(5): 600-604.
李歌, 席作武, 曹琳果, 等. 肠道菌群与化浊解毒理论视角下溃疡性结肠炎发病机制及疗效研究[J]. 辽宁中医药大学学报, 2026, 28(5): 124-130.
贾雪梅. 基于肠道菌群与细胞焦亡调控代谢物探讨化浊解毒方治疗溃疡性结肠炎的作用机制[D]. 石家庄: 河北中医药大学, 2023.
Hu J Y, Chen H X, Zhu L, et al. Baitouweng Decoction modulates gut microbial production of indole-3-propionic acid and epithelial necroptosis to alleviate DSS-induced colitis in mice [J]. Chin Med, 2025, 20(1): 119.
郑敏, 赵琰, 李彤, 等. 葛根红藤解毒汤对浊毒内蕴型溃疡性结肠炎患者血清NLRP3炎症小体、IL-18、IL-1β及对肠道菌群、黏膜屏障的影响[J]. 中国中西医结合消化杂志, 2024, 32(1): 30-34.
尚立宇. 基于TLR4/NF-κB/NLRP3信号通路探讨四神丸改善肠道菌群结构防治脾肾阳虚型UC小鼠的机制研究[D]. 兰州: 甘肃中医药大学, 2025.
Huang H J, Yang C Y, Li S L, et al. Lizhong Decoction alleviates experimental ulcerative colitis via regulating gut microbiota-SCFAs-Th17/Treg axis [J]. J Ethnopharmacol, 2025, 349:119958.
华明柳, 沈杰, 赵园园. 大黄附子汤合桃花汤加味对溃疡性结肠炎患者肠道菌群及肠屏障功能的影响[J]. 中医药学报, 2023, 51(6): 84-88.
Luo Y T, Fu S, Liu Y L, et al. Banxia Xiexin Decoction modulates gut microbiota and gut microbiota metabolism to alleviate DSS-induced ulcerative colitis [J]. J Ethnopharmacol, 2024, 326: 117990.
Wang X J, Huang S W, Zhang M L, et al. Gegen Qinlian Decoction activates AhR/IL-22 to repair intestinal barrier by modulating gut microbiota-related tryptophan metabolism in ulcerative colitis mice [J]. J Ethnopharmacol, 2023, 302: 115919.
Chen W, Xu L, Wang L, et al. Qing-Re-Hua-Shi Decoction ameliorates DSS-induced colitis by modulating multiple signaling pathways and remodeling the gut microbiota and metabolite profile [J]. Front Cell Infect Microbiol, 2025, 15: 1541289.
Jiao C H, Zhang Q W, Yang M J, et al. Shenling Baizhu San ameliorates ulcerative colitis by regulating the gut microbiota and its tryptophan metabolites: A complementary medicine to mesalamine [J]. J Ethnopharmacol, 2022, 291: 115145.
Cui L, Guan X N, Ding W B, et al. Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota [J]. Int J Biol Macromol, 2021, 166: 1035-1045.
Li Z Y, Lin L H, Liang H J, et al. Lycium barbarum polysaccharide alleviates DSS-induced chronic ulcerative colitis by restoring intestinal barrier function and modulating gut microbiota [J]. Ann Med, 2023, 55(2): 2290213.
Zhang Q W, Yang M J, Liao C Y, et al. Atractylodes macrocephala Koidz polysaccharide ameliorates DSS-induced colitis in mice by regulating the gut microbiota and tryptophan metabolism [J]. British J Pharmacology, 2025, 182(7): 1508-1527.
Wu H, Li Y L, Wang Y, et al. Anemoside B4 alleviates ulcerative colitis by attenuating intestinal oxidative stress and NLRP3 inflammasome via activating aryl hydrocarbon receptor through remodeling the gut microbiome and metabolites [J]. Redox Biol, 2025, 85: 103746.
Cheng H, Liu J, Zhang D D, et al. Ginsenoside Rg₁ alleviates acute ulcerative colitis by modulating gut microbiota and microbial tryptophan metabolism [J]. Front Immunol, 2022, 13: 817600.
Wang C X, Liu H L, Li Z Q, et al. Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation [J]. Biomed Pharmacother, 2024, 180: 117534.
Dong Y L, Fan H, Zhang Z, et al. Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway [J]. Int J Biol Sci, 2022, 18(4): 1381-1397.
Li C L, Deng L, Pu M, et al. Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome [J]. J Ethnopharmacol, 2024, 335: 118680.
Mao N, Yu Y, He J, et al. Matrine ameliorates DSS-induced colitis by suppressing inflammation, modulating oxidative stress and remodeling the gut microbiota [J]. Inter J Mol Sci, 2024, 25(12): 6613.
Wu Z H, Huang S M, Li T T, et al. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis [J]. Microbiome, 2021, 9(1): 184.
Qu Y F, Li X Y, Xu F Y, et al. Kaempferol alleviates murine experimental colitis by restoring gut microbiota and inhibiting the LPS-TLR4-NF-κB axis [J]. Front Immunol, 2021, 12: 679897.
He X D, Li M, Zuo X D, et al. Kushenol I combats ulcerative colitis via intestinal barrier preservation and gut microbiota optimization [J]. World J Gastroenterol, 2025, 31(26): 105656.
Su Y L, Liang J J, Zhang M L, et al. Wogonin regulates colonocyte metabolism via PPARγ to inhibit Enterobacteriaceae against dextran sulfate sodium-induced colitis in mice [J]. Phytother Res, 2023, 37(3): 872-884.
Wang W P, Xia T S, Yu X P. Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-κB pathway in vitro [J]. Inflamm Res, 2015, 64(6): 423-431.
Jia Y H, Liu X J, Gao X Y, et al. Plantamajoside alleviates DSS-induced ulcerative colitis by modulating gut microbiota, upregulating CBS, and inhibiting NF-κB [J]. Phytomedicine, 2025, 143: 156827.
姜佳恩. 基于PI3K/AKT、TRL4/NF-κB通路黄芪-青黛内外联合治疗溃疡性结肠炎的作用机制[D]. 南昌: 江西中医药大学, 2024.
李红燕. 黄连配伍厚朴调控溃疡性结肠炎肠道菌群的作用机制研究[D]. 成都: 成都中医药大学, 2021.
魏海梁, 李京涛, 陈志国, 等. 小檗碱与6-姜烯酚配伍对溃疡性结肠炎小鼠肠道炎症和菌群影响的实验研究[J]. 中国中药杂志, 2022, 47(16):4418-4427.
Jiang Y W, Xu H C, Wu J L, et al. A hierarchically assembled oral formulation with drug-convertible carriers for targeted ulcerative colitis therapy through a three-pronged strategy [J]. Adv Compos Hybrid Mater, 2025, 8(4): 280.

2026年第57卷第16期

PDF下载

101

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.16.033

接收时间：2026-05-28
首发时间：2026-10-22
出版时间：2026-08-28

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-05-28

基金

国家自然科学基金青年基金项目

兰州市科技计划项目

作者信息

^1.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050

^2.甘肃中医药大学中西医结合学院, 甘肃兰州 730000

^3.中国人民解放军联勤保障部队第九四〇医院消化内科, 甘肃兰州 730050

通讯作者:

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.16.033

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT